NasdaqGM:MAZEPharmaceuticals
Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain##
Maze Therapeutics stock has delivered a strong 59.2% return over the past year, yet its low value score and an overvalued read on market multiples suggest investors are paying up without a clear margin of safety.
Over the last 12 months, Maze Therapeutics has returned 59.2%, which puts the spotlight on whether recent gains already reflect much of the good news investors expect.
Future progress in turning its pipeline into consistent, scalable cash flows can support the current share price,...